Idiopathic optic neuritis (ON) and nonarteritic anterior ischaemic optic neuropathy (AION) are acute optic neuropathies with overlapping clinical profiles. ON typically presents as painful loss of vision in younger patients and has a good potential for improvement, whereas AION typically presents as painless loss of vision in the middle aged or elderly with usually less recovery. Although in many cases the diagnosis of these optic neuropathies is straightforward, neither the presence of pain, age of the patient, nor a variety of other features can confidently distinguish between the two disorders. ' Neural network analysis is an artificial intelligence technique for the classification of groups, and thus is well suited to computer aided diagnosis. The neural network itself is a simulation of a set of neurons, organised in layers (Fig 1) . The advantages of neural networks for classification, as well as rationales for its application, are well summarised in a recent application to classifying automated perimetry visual fields. 2 We describe here the use of neural network analysis to help differentiate between ON and AION, and to generate guidelines for distinguishing these conditions when they overlap clinically.
Materials and methods
PATIENT SELECTION CRITERIA Patient records from the neuro-ophthalmology database at the Massachusetts Eye and Ear Infirmary were analysed retrospectively. All of the patients were described previously in a study of overlapping profiles of ON and AION,' with some excluded because of insufficient data on the initial or follow up visits. Details of the clinical examination were as described in that reference. Every patient given a clinical diagnosis of either ON or AION by one of two experienced neuroophthalmologists (JR or SL), seen within 2 weeks of presentation, and followed for at least 4 months until stabilisation of visual function was selected. The diagnosis was one based purely on clinical impression, and not on any particular criteria. Patients with hereditary disorders, temporal arteritis, or other granulomatous inflammations or vasculitides, infection, or traumatic optic neuropathy were excluded.
There were 244 patients with optic neuropathies clinically diagnosed as ON or AION, and these were divided into two groups. Firstly, a group of 116 patients with 'gold standard' diagnoses was defined retrospectively (Fig 2) . Specifically, a 'gold standard' diagnosis of ON was assigned when the patient subsequently developed multiple sclerosis; 69 patients met this criterion. A gold standard diagnosis of AION was assigned when the patient had no pain, was over the age of 60, and had disc oedema; 47 patients met these criteria. These two definitions were consistent with the 'gold standard criteria' of Rizzo and Lessell.1 The gold standard groups of patients was used to train a neural network (see below).
The remaining 128 patients (90 patients with presumed ON and 38 patients with presumed AION) formed a second group, which was subsequently used to test how often the network diagnosis matched the diagnosis of the expert clinician. These patients did not meet the gold standard criteria enumerated above, and their diagnosis was based simply on clinical impression at the time of first examination by the examining neuro-ophthalmologist, and not on any specific criteria.
NEURAL NETWORK DESIGN
The majority of neural networks contain three layers of neurons, and a similar format was At this point the network was considered to have 'learned' the gold standard patient data. The network was then presented with data from the non-gold standard patients, to determine whether the network would agree with the expert clinician. A diagnosis of ON by the network was recorded if the ON neuron in the output layer had a greater value than the AION neuron, and vice versa. The agreement between the diagnosis calculated by the network and the clinical diagnosis of the expert clinicians was tabulated in a 2 x 2 To assess the relative contribution of the hidden layer (see Fig 1) Specifically, in the first (training) phase, the network was presented in random order with the data from 116 patients with gold standard ON or AION. After this was repeated 342 times, or almost 40 000 (116 x 342 = 39 672) distinct training episodes, the network had learned these gold standard cases well enough so that its error rate was minimised. In other words, there was complete internal consistency in making the diagnoses (that is, no errors) when the network was retested with the data with which it was trained.
To further validate the training process, the patients from the gold standard diagnosis groups were subdivided into four sets, and a The groups where the network and the clinician agreed on the diagnosis of ON and AION ('concordant' groups; groups I and III) were compared with those where there was disagreement ('discordant' groups; groups II and IV). These data are summarised in The patients incorrectly diagnosed by the network to have ON (group IV) were similar to those who actually had AION, except that they both had central scotomas.
The importance of each of the clinical criteria was assessed by tabulating the network predictions while each of the clinical variables was systematically varied (Table 3) . All values were compared with an idealised patient for whom there was an equal probability of ON and AION. Relative youth, female sex, better initial acuity, presence of a central scotoma, subsequent improvement in acuity, or progressive disease all biased the network towards a diagnosis of ON. Advanced age, male sex, presence of hypertension, poor initial acuity, an altitudinal field defect, disc oedema, or less improvement in acuity biased the network toward a diagnosis of AION.
The effect of varying the size of the hidden layer of the neural network was studied, using values of 1, 2, 4, 8, 16 , and 32 neurons in the layer. There was an inverse relation between the size of the hidden layer and the number of trials necessary for training to take place (Fig  3) . There was little difference in the accuracy of the network across different hidden layer sizes (range 96.7-97.8%).
Discussion
Neural networks have been used as artificial intelligence tools for modelling functions of the brain, including the visual and oculomotor systems. 45 They have also been used as aids for diagnosis or classification, in areas as diverse as karyotyping banded chromosomes,6 differentiating the histological features of neoplasms,7 diagnosing myocardial infarction from enzyme data,8 analysing positron emission tomography scans for features typical of Alzheimer's disease,9 and distinguishing glaucomatous from non-glaucomatous automated visual fields.2 Neural networks are capable of distinguishing groups based on a wide variety of input variables, without a priori knowledge of which features are important in the input data. There is theoretical evidence that neural Because the neural network method is a powerful one for classifying groups, we studied its applicability to distinguish optic neuropathies which overlap clinically.' We used data from our retrospective study of patients with either ON or AION, and found that the network had a high agreement with experienced clinicians in distinguishing the two optic neuropathies. The fact that the neural network almost completely distinguished the gold standard patients, even when trained on a subset of these patients and tested on another subset (validation analysis), suggests that there are reliable features that separate these patients.
The importance of each clinical feature in distinguishing the two groups was examined by varying the input from each feature in turn. The data from this analysis (Table 3) confirm the general teaching that ON is more likely to be associated with youth, female sex, central scotoma, and good improvement in acuity, whereas AION is more likely to be associated with advanced age, altitudinal field defect, disc oedema, and less improvement. Interestingly, initial good acuity was more likely to be associated with ON, and poor initial acuity with AION. This finding was not evident in our earlier report, probably because acuity was analysed as a univariate factor while the neural network takes covarying factors into account. Whether this reflects population differences or simply selection bias in a referral population cannot be determined.
The clinicians and the network were not always in agreement. The network made the same diagnoses as the clinicians in 97.8% of the patients with ON and 94.7% of the patients with AION; two patients in each group had discordant diagnoses. There are at least two ways to explain the discrepant diagnoses found in these discordant groups. One possibility is that the clinicians were correct, and the network erroneously extrapolated data from the gold standard groups. Alternatively, the clinicians may have been incorrect. The two patients incorrectly diagnosed by the network with AION were middle aged, had subacute onset of severe visual loss, disc oedema, no pain, and did not improve over time. Many of these features are characteristic of AION, except for the age and tempo of visual loss. It is therefore debatable whether these patients truly had ON or AION. The two patients incorrectly diagnosed by the network with ON were similar to the patients with AION, but had central scotomas, a classic field defect in ON. One of these patients was 79 years old, and his acuity slightly worsened over time. If this patient actually had ON, then the relative lack of improvement in acuity is consistent with reports of a decreased tendency of elderly patients with multiple sclerosis to recover function.'415
The lack of correlation of hidden layer size and diagnostic accuracy might suggest that much of the information needed to discriminate the two groups does not require a hidden layer, and therefore is of low complexity. How 
